Acrivon Therapeutics, Inc. (ACRV)
2.10
+0.04
(+1.94%)
USD |
NASDAQ |
Aug 31, 16:00
2.05
-0.05
(-2.38%)
After-Hours: 17:40
Acrivon Therapeutics Debt to Equity Ratio : 0.0244 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0244 |
| March 31, 2026 | 0.0253 |
| December 31, 2025 | 0.0241 |
| September 30, 2025 | 0.0232 |
| June 30, 2025 | 0.0228 |
| March 31, 2025 | 0.0219 |
| December 31, 2024 | 0.0206 |
| September 30, 2024 | 0.0204 |
| June 30, 2024 | 0.0195 |
| March 31, 2024 | 0.0412 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.0383 |
| September 30, 2023 | 0.032 |
| June 30, 2023 | 0.0308 |
| March 31, 2023 | 0.0298 |
| December 31, 2022 | 0.0291 |
| September 30, 2022 | 0.0668 |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | -5.382 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 99.09M |
| Total Liabilities (Quarterly) | 12.43M |
| Shareholders Equity (Quarterly) | 86.66M |
| Current Ratio | 7.993 |
| Net Debt Paydown Yield | 0.37% |